Price
CHART BY
Frequently asked questions
What is 23andMe's market capitalization?
The market capitalization of 23andMe is $35.14M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for 23andMe?
23andMe's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -15.72. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for 23andMe's stock?
Currently, 2 analysts cover 23andMe's stock, with a consensus target price of $8.40. Analyst ratings provide insights into the stock's expected performance.
What is 23andMe's revenue over the trailing twelve months?
Over the trailing twelve months, 23andMe reported a revenue of $208.78M.
What is the EBITDA for 23andMe?
23andMe's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$190.03M. EBITDA measures the company's overall financial performance.
What is the free cash flow of 23andMe?
23andMe has a free cash flow of -$155.63M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does 23andMe have, and what sector and industry does it belong to?
23andMe employs approximately 582 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of 23andMe's shares?
The free float of 23andMe is 13.98M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $35.14M
- EPS (TTM)
- -15.72
- Free Float
- 13.98M
- Revenue (TTM)
- $208.78M
- EBITDA (TTM)
- -$190.03M
- Free Cashflow (TTM)
- -$155.63M
Analyst Ratings
The price target is $8.40 and the stock is covered by 2 analysts.
Buy
1
Hold
0
Sell
1
Information
23andMe Holding Co. is a consumer genetics and research company, which engages in assisting people to access, understand, and benefit from the human genome. It operates through the Consumer and Research Services, and Therapeutics segments. The Consumer and Research Services segment consists of Personal Genome Service, Telehealth Business, and Research Services. The Therapeutics segment focuses on the genetic insights of genetic and phenotypic information. The company was founded by Anne E. Wojcicki in 2006 and is headquartered in San Francisco, CA.
- Employees
- 582
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- ISIN
- US90138Q3065
- Primary Ticker
- ME
Knockouts
LSX Data · Fundamentals & EOD data from FactSet